Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Long-Term Progression-Free Survival in Patients Treated With RVD Induction and Risk-Adapted Maintenance.","authors":"Lilly Gu, Om Raval, Xiyuan Angel Ji, Nisha Joseph, Craig C Hofmeister, Vikas A Gupta, Richa Parikh, Nishi Shah, Roberto Mina, Jeffrey Switchenko, Lawrence Boise, Sagar Lonial, Ajay K Nooka, Jonathan L Kaufman","doi":"10.1016/j.clml.2026.09.013","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.013","url":null,"abstract":"<p><strong>Background: </strong>A subset of patients with newly diagnosed multiple myeloma (NDMM) achieves prolonged remission following modern induction and maintenance, but predictors of long-term progression-free survival (PFS) and the durability of remission beyond a decade remain incompletely defined.</p><p><strong>Methods: </strong>We retrospectively analyzed 1000 consecutive NDMM patients treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction followed by risk-adapted maintenance from 2007 to 2016. Patients diagnosed after October 2015 were excluded to ensure ≥10 years of follow-up. Long-term progression-free survivors (LT-PFS) were defined as remaining progression-free for ≥10 years. Demographics, clinical characteristics, and outcomes were compared between LT-PFS and non-LT-PFS groups, and logistic regression identified predictors of LT-PFS. Survival was estimated by the Kaplan-Meier method, with a landmark analysis among patients progression-free at 10 years.</p><p><strong>Results: </strong>Among 774 patients analyzed, 165 (21.3%) achieved LT-PFS. Compared with non-LT-PFS patients, LT-PFS patients were younger, had lower disease stage, more favorable cytogenetics, more often received maintenance therapy, and achieved deeper responses to induction therapy. Median cohort PFS was 4.6 years, with a 10-year PFS rate of 26.2%. Landmark analysis demonstrated continued risk of late events, with 17% of LT-PFS patients experiencing progression or death beyond 10 years, and median PFS not reached.</p><p><strong>Conclusion: </strong>Approximately one-fifth of NDMM patients treated with RVD-based therapy achieved sustained remission at 10 years, though a meaningful risk of late relapse persisted. Favorable disease biology, younger age, and maintenance therapy are associated with long-term PFS. These findings define a clinically relevant long-term remission state and provide a benchmark for evaluating outcomes with contemporary quadruplet regimens.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma.","authors":"Prokop Vodička, Michal Masár, Carrie A Thompson, David Belada, George A Cholack, Kateřina Benešová, Izidore S Lossos, Heidi Móciková, Diana Maláriková, AnnaLynn M Williams, Vít Procházka, Kamila Polgárová, Chijioke C Nze, Juraj Ďuraš, Jan Kořen, Jonathon B Cohen, Kateřina Steinerová, Jana Šálková, Andrew L Feldman, Josef Karban, Eric Mou, Alice Sýkorová, Petra Kovaříková, Elliot J Cahn, Aleš Obr, Eva Konířová, Peter Martin, Jitka Dlouhá, Mazie Tsang, Dilan Patel, Petra Blahovcová, Patrick M Reagan, David Jaye, Magdalena Klánová, Jonathan W Friedberg, Vít Campr, Christopher R Flowers, Pavel Klener, Matthew J Maurer, Thomas M Habermann, Marek Trněný, James R Cerhan","doi":"10.1016/j.clml.2026.09.015","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.015","url":null,"abstract":"<p><strong>Background: </strong>Patients aged 80+ years with large B-cell lymphoma (LBCL) represent a growing, vulnerable population where conventional prognostic indices inadequately capture comorbidity burden. We evaluated prognostic value of the Lymphoma Epidemiology of Outcomes Comorbidity Index (LCI) and derived simplified comorbidity model.</p><p><strong>Methods: </strong>In 539 patients aged 80+ years with LBCL from two independent international cohorts, we evaluated associations between comorbidities/LCI (10 comorbidity categories) and overall survival (OS) or event-free survival (EFS). discrimination and model fit were assessed using C-indices and likelihood ratio tests.</p><p><strong>Results: </strong>LCI categories were 0 (19%), 1 (31%), 2+ (50%). Higher LCI predicted inferior OS (LCI 1 vs. 0: hazard ratio [HR] = 1.43 [95% CI 1.04-1.97]; LCI 2+ vs. 0: HR = 1.88 [1.40-2.53]), EFS (LCI 1 vs. 0: HR = 1.37 [1.00-1.87]; LCI 2+ vs. 0: HR = 1.78 [1.33-2.38]), and higher 2-year nonlymphoma mortality (11%, 13%, and 26% for LCI 0, 1, and 2+). Heart disease (48%), prior or concurrent malignancy (9%), and stroke (8%) independently predicted OS and were combined into the MaSH Comorbidity Index (MaSH-CI; one point each), with scores 0 (44%), 1 (47%), and 2+ (9%). Higher MaSH-CI predicted inferior OS (1 vs. 0: HR = 1.59 [1.27-1.98]; 2+ vs. 0: HR = 2.43 [1.70-3.47]). Adding LCI or MaSH-CI to International Prognostic Index (IPI) or SENIOR-IPI significantly improved model fit and discrimination across all endpoints (ΔC-index 0.02-0.03).</p><p><strong>Conclusion: </strong>Multimorbidity strongly predicts outcomes in LBCL patients aged 80+ years. The simplified MaSH-CI adds prognostic value beyond conventional prognostic indices and offers a practical tool for risk-adapted management.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation.","authors":"Huazhou Shi, Dapeng Peng, Nannan Qi, Yan Wang, Zhiyun Niu, Jingyu Zhang","doi":"10.1016/j.clml.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.006","url":null,"abstract":"<p><strong>Introduction: </strong>We assessed the efficacy and safety of azacitidine (AZA) in patients with RUNX1::RUNX1T1 measurable residual disease (MRD)-positive acute myeloid leukemia (AML) after consolidation who did not undergo allogeneic hematopoietic stem-cell transplantation (allo-HSCT), and descriptively compared outcomes with a contemporaneous allo-HSCT cohort.</p><p><strong>Methods: </strong>We retrospectively analyzed 60 patients with persistent/recurrent RUNX1::RUNX1T1 MRD positivity after consolidation (46 received AZA, 14 underwent allo-HSCT). Progression-free survival (PFS; primary endpoint), cumulative incidence of relapse (CIR), overall survival (OS) and complications were assessed.</p><p><strong>Results: </strong>After median follow-up 36 months, 3-year PFS and OS were 65.0% and 71.1%. The 3-year CIR was higher with AZA than allo-HSCT (37.0% vs. 7.1%; Gray P = .046), whereas no statistically significant differences in PFS (63.0% vs. 71.4%; log-rank P = .68) or OS (70.8% vs. 71.4%; log-rank P = .93) were observed; this comparison was exploratory and underpowered. KIT mutation, not treatment group, independently predicted shorter PFS and OS. AZA patients had fewer complications and no treatment-related deaths.</p><p><strong>Conclusion: </strong>In this small, retrospective, non-randomized study, AZA was associated with a higher relapse incidence than allo-HSCT; no significant differences in PFS or OS were observed, although the study was underpowered to establish equivalence. AZA showed favorable toxicity and may represent a feasible option for MRD-positive patients who do not undergo transplant. Larger prospective studies are needed.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6\"[Clinical Lymphoma Myeloma and Leukemia 26 (2026) 317-327].","authors":"David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, Fernando Vargas Madueno, Sami Ibrahimi, Seema Naik, Mitul Gandhi, Julie Erika Haydu, Bradley Lash, Mark Fesler, John Hrom, Eric H Lee, Suchitra Sundaram, Kristin Conte, Kojo Osei-Bonsu, Thomas Doerr, Yang Bai, Neha Dixit, Christian W Eskelund, Alexander P Boardman, Ralph Boccia, Christina Y Lee, Jeff P Sharman","doi":"10.1016/j.clml.2026.08.006","DOIUrl":"https://doi.org/10.1016/j.clml.2026.08.006","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Patients With Acute Promyelocytic Leukemia in Jordan: Real-World Data from a Tertiary Referral Center.","authors":"Mohammad Harb, Leen Al-Kraimeen, Rawan Hamamreh, Lina Alkhdour, Abdelrahman Sullaiman, Omar Shahin, Waleed Dana, Kamal Al-Rabie, Yosra Al-Masri, Osama Alsmadi, Nazmi Kamal, Nidal Al-Masri, Fareed Barakat, Mohamad Makoseh, Zaid Abdel Rahman","doi":"10.1016/j.clml.2026.09.012","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.012","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Prognostic Analysis of Pediatric Acute Myeloid Leukemia With CBFB::MYH11: A 10-Year Single-Center Cohort Study.","authors":"Zhi-Xiao Zhang, Lin Zhang, Ai-Dong Lu, Le-Ping Zhang, Yue-Ping Jia, Hui-Min Zeng","doi":"10.1016/j.clml.2026.09.011","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.011","url":null,"abstract":"<p><strong>Introduction: </strong>CBFB::MYH11-positive AML is classified as favorable-risk, yet outcomes vary. The prognostic roles of KIT mutations, additional chromosomal abnormalities (ACAs), and minimal residual disease (MRD) kinetics remain debated, particularly in Chinese pediatric cohorts.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 66 consecutive pediatric patients with CBFB::MYH11-positive AML. Cytogenetic and molecular data were collected, and MRD was monitored by real-time quantitative PCR. Overall survival (OS), event-free survival (EFS), and cumulative incidence of relapse (CIR) were estimated using Kaplan-Meier and competing risk methods.</p><p><strong>Results: </strong>At a median follow-up of 65 months, 5-year OS, EFS, and CIR were 97.0%, 88.7%, and 8.6%. KIT mutations were present in 56.1% and were not associated with EFS (hazard ratios 0.58, 95% confidence interval 0.13-2.59). ACAs correlated with lower first-course remission rates and higher central nervous system leukemia incidence but not survival. Postinduction MRD positivity was almost universal (94.9%), and no MRD cut-off at assessed time points was associated with EFS. Of 13 transcript re-emergences, 3 progressed to relapse, and 8 (peak ≤0.14%) did not, 4 without therapy modification. Five-year EFS was 90.4% with chemotherapy in first complete remission (CR1; n = 58) and 100% after CR1 transplantation (n = 6).</p><p><strong>Conclusion: </strong>This study confirms excellent prognosis of pediatric CBFB::MYH11-positive AML with modern therapy. Owing to the few events, it could neither establish nor exclude an effect of traditional risk factors. Low-level molecular re-emergence frequently resolved without relapse, and the data are consistent with, but do not independently establish, current recommendations against routine CR1 transplantation. Larger studies are needed to identify patients for treatment intensification.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supportive Care in Multiple Myeloma: Evidence-Based Recommendations From the Intergroupe Francophone du Myélome (IFM).","authors":"Laurent Frenzel, Pascal Godmer, Alexis Talbot, Cécile Sonntag, Stéphanie Harel, Thomas Chalopin, Salomon Manier, Cyrille Hulin, Thierry Facon, Lionel Karlin, Jill Corre, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Olivier Decaux, Bertrand Arnulf, Chanaz Louni, Mohamad Mohty, Aurore Perrot, Emilie Chalayer, Murielle Roussel","doi":"10.1016/j.clml.2026.09.008","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.008","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a largely incurable plasma cell malignancy in which disease- and treatment-related complications substantially impair quality of life and survival, making supportive care a central determinant of outcome. This review presents unified, evidence-based recommendations from the Intergroupe Francophone du Myélome across 7 domains of supportive care and their implications for contemporary practice, including the era of T-cell-redirecting immunotherapy. With the advent of highly effective induction regimens, autologous stem cell transplantation, immunomodulatory drugs, proteasome inhibitors, anti-CD38 monoclonal antibodies, bispecific antibodies (BsAbs), and chimeric antigen receptor T-cell (CAR-T) therapies, the prevention and management of treatment-emergent toxicities and disease-related sequelae have become increasingly complex. Synthesizing a structured review of the literature, international guidelines, and formal expert consensus, we provide practical recommendations for (1) venous thromboembolism prophylaxis, (2) prevention of skeletal-related events with bone-modifying agents, (3) prevention of infectious complications, (4) vaccination, (5) management of MM-related anemia with erythropoiesis-stimulating agents, (6) adapted physical activity, and (7) practical guidance for the management of treatment-emergent peripheral neuropathy, with particular attention to the specific challenges introduced by BsAbs and CAR-T therapy. By consolidating these 7 domains into a single framework applicable across all lines of therapy, from first-line treatment to relapsed/refractory disease, this review offers a pragmatic reference intended to standardize and improve supportive care and, ultimately, patient outcomes and health-related quality of life in MM. Positions that deliberately differ from other international guidelines-notably those of the International Myeloma Working Group-are explicitly identified and justified.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.","authors":"Hosana Candreva, Mehak Dang, Henrique Guimarães Barbosa Coelho, Yujin Jeong, Fahad Alabbas, Akihiro Miyashita","doi":"10.1016/j.clml.2026.09.009","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.009","url":null,"abstract":"<p><p>The optimal initial management of asymptomatic patients with advanced-stage low-tumor-burden follicular lymphoma (LTB-FL) remains uncertain. Although watchful waiting (WW) has historically been the standard approach, rituximab monotherapy has emerged as an alternative strategy. A systematic review and meta-analysis comparing rituximab monotherapy with WW was performed in this population. PubMed, Embase, and Cochrane Library were systematically searched for studies comparing rituximab monotherapy with WW in adult patients with advanced-stage LTB-FL. The primary outcome was overall survival (OS), while secondary outcomes included histological transformation (HT) and time to new treatment (TTNT). Statistical analyses were conducted using Review Manager version 5.4 with random-effects models, and heterogeneity was assessed using the I² statistic. Three studies, including 2 randomized controlled trials and one observational study, comprising 1590 patients, were included. For OS, analysis demonstrated no statistically significant difference between rituximab and WW (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.70-1.12; P = .31; I² = 0%). Similarly, rituximab was not associated with a statistically significant reduction in HT (risk ratios 0.84, 95% CI 0.60-1.16; P = .29; I² = 0%), although the pooled estimates for OS and HT numerically favored rituximab. TTNT was significantly prolonged with rituximab compared with WW (HR 0.50, 95% CI 0.41-0.61; P < .00001; I² = 0%). Early rituximab monotherapy was not associated with improved OS or a significant reduction in HT compared with WW in asymptomatic patients with advanced-stage LTB-FL, although it prolonged TTNT. Further prospective studies are warranted to define the long-term clinical impact of early rituximab.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing Patterns of Causes of Death in Patients With Multiple Myeloma During the Modern Therapeutic Era.","authors":"Abel Rosado-Rodriguez, Esther Ortega-Vida, Antonio Cárdenas-Cruz, Rocío Fe, Victoria Verdugo, Rocío Gavira, Beatriz Rossi-Vargas, Irene López-Pulido, Pilar Hernández-Sánchez, Sebastián Garzón","doi":"10.1016/j.clml.2026.09.004","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.004","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic advances have substantially prolonged survival in multiple myeloma (MM). However, real-world evidence on temporal changes in causes of death remains limited. This study evaluated how mortality patterns have evolved during the era of novel therapies.</p><p><strong>Patients and methods: </strong>We conducted a retrospective real-world cohort study including 469 consecutive patients with MM managed at a tertiary referral center between 2000 and 2025. The primary analysis included 230 patients who died between 2008 and 2025. Causes of death were independently adjudicated by 2 hematologists using a predefined hierarchical classification based on the underlying cause of death.</p><p><strong>Results: </strong>MM progression remained the leading cause of death but declined significantly across study periods, from 86.4% in 2008 to 2013 to 62.5% in 2020 to 2025 (P = .001). Conversely, non-MM-related deaths increased from 7.6% to 31.8%. Early deaths decreased significantly (28.8% vs. 9.1%; P = .004). Cardiovascular and infectious terminal events became more frequent, whereas multiorgan failure became less frequent.</p><p><strong>Conclusion: </strong>The distribution of causes of death among deceased patients with MM has changed over time, with a declining proportion of deaths due to disease progression and an increasing contribution of competing non-MM causes. As survival improves, these findings support integrating cardiovascular care, infection prevention, and long-term management of comorbidities into MM survivorship strategies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection Prevention and Management in Patients With Multiple Myeloma Treated With Bispecific Antibodies: A Case-Based Approach for Routine Clinical Practice.","authors":"Lorenzo Cani, Michele Puppi, Silvia Corcione, Carmine Liberatore, Silvia Mangiacavalli, Gregorio Barilà, Maddalena Giannella, Ombretta Annibali, Alessandra Romano, Corrado Girmenia, Barbara Veggia, Roberto Mina, Elena Zamagni","doi":"10.1016/j.clml.2026.09.003","DOIUrl":"https://doi.org/10.1016/j.clml.2026.09.003","url":null,"abstract":"<p><p>Patients with multiple myeloma (MM) treated with bispecific antibodies (BsAbs) represent a particularly vulnerable population for infectious complications due to profound disease-related immune dysfunction, and treatment-related immunosuppression. In addition, BsAbs themselves induce sustained T-cell activation and prolonged immune modulation, which, while highly effective for disease control, are associated with a relevant and sometimes severe infectious burden. As these therapies move into earlier lines of treatment and are administered over extended periods, optimizing infection prevention and management strategies has become a critical component of routine clinical practice. In this review, we present a case-based approach to infection prevention and management in MM patients receiving BsAbs. The first case focuses on baseline risk assessment and prophylactic strategies prior to and after treatment initiation. The second case addresses the diagnostic and therapeutic approach to febrile episodes occurring during therapy, with emphasis on early recognition, risk stratification, and empiric antimicrobial treatment. The third case discusses the diagnosis and management of opportunistic infections, highlighting the importance of tailored diagnostic work-up and pathogen-directed therapy in this highly immunocompromised setting. Through these clinical scenarios, we aim to provide a practical framework for implementing individualized infection prevention and management strategies in this rapidly expanding patient population within the evolving therapeutic landscape of MM.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}